TORONTO, Apr. 22, 2015 /PRNewswire/ -- Axxess Pharma
Inc. (OTC: AXXE) a specialty pharmaceutical and nutritional
supplements company is pleased to announce they have signed a
long-term manufacturing, marketing and distribution agreement with
8E6Tong Private Company Ltd (Tong)., a Singapore-registered company with a
manufacturing facility located in Tongxiang, China.
Under the agreement, Tong will be launching its own brand of
products using Axxess' patented formula. Tongs products will be
sold online, world-wide and in select retail outlets. Axxess Pharma
projects minimum sales of $525,000
USD in the first year and $4,308,000
USD in the initial 5 year term of the license.
Tong is focused on the production, marketing, and distribution
of health sciences products to improve the quality of life.
The facility has been involved in the application of environmental
science and green chemistry since 2010.
"This deal represents a major milestone for Axxess Pharma, and
validates the value of our Intellectual Property. Revenues are
expected to begin in the third quarter 2015 and accelerate year
over year." stated Dr. Bagi
President of Axxess Pharma Inc.
About Axxess Pharma Inc.:
Axxess Pharma Inc. is a Nevada Corporation operating through its
wholly owned Canadian Subsidiary: Axxess Pharma Canada Inc.,
headquartered in Toronto. Axxess
is a specialty Health Care Products Company dedicated to improving
health and quality of life by offering select medicines,
nutritional supplements and over the counter remedies all across
the Americas. Axxess's goal is to bring additional products to the
market and provide new, innovative options for better health
spanning areas such as high cholesterol, blood pressure, acute pain
-- to optimal health management through improved nutritional
supplements. To learn more about our new products TapouT Extreme
Muscle Growth and TapouT Muscle Recovery, please visit:
http://buytapoutme.com and http://www.tapoutmusclerecovery.com.
For more information, please visit www.axxesspharmainc.com, or
contact Investor Relations at (973) 351-3868.
About Authentic Brands Group, LLC
Authentic Brands Group, is a brand development, licensing, and
entertainment company. In conjunction with Leonard Green & Partners, ABG's mandate to
acquire, manage, and elevate long-term value in consumer,
celebrity, and media brands. Headquartered in New York City, ABG's mission is to further
enhance brand equity through partnering with best-in-class
licensees and retail partnerships. ABG's global portfolio of
world-renowned brands includes Marilyn Monroe®, Mini Marilyn™,
Muhammad Ali®, Elvis Presley®, Juicy Couture®, Judith Leiber®,
Adrienne Vittadini®, Taryn Rose®, Hickey Freeman®, Hart Schaffner
Marx®, Palm Beach®, Misook®, Prince®, Spyder®, Airwalk®, Above The
Rim®, Vision Street Wear®, Hind®, Ektelon®, Viking®, Bobby Jones®,
TapouT®, Sportcraft®. www.abg-nyc.com.
Safe Harbor Statement
Statements about the Company's future expectations and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby.
The above information contains information relating to the Company
that is based on the beliefs of the Company and/or its management,
as well as assumptions made by any information currently available
to the Company or its management. When used in this document, the
words "anticipate," "estimate," "expect," "intend," "plans,"
"projects," and similar expressions, as they relate to the Company
or its management, are intended to identify forward-looking
statements. Such statements reflect the current view of the Company
regarding future events and are subject to certain risks,
uncertainties and assumptions, including the risks and
uncertainties noted. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
to be incorrect, actual results may vary materially from those
described herein as anticipated, believed considered in light of
the accompanying meaningful cautionary statements herein. Factors
that could cause results to differ include, but are not limited to,
successful performance of internal plans, the impact of competitive
services and pricing and general economic risks, estimated,
expected, intended or projected. In each instance, forward-looking
information should be and uncertainties.
Contact:
Investor Relations
Taylor Capitol, Inc.
Stephen Taylor
+1-973-351-3868
Staylor@TheStockAlerts.com
www.TheStockAlerts.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/axxess-pharma-signs-major-manufacturing-marketing-and-distribution-agreement-with-chinese-manufacturer-300070069.html
SOURCE Axxess Pharma, Inc
